```html

Fetal Growth Restriction (FGR)

Overview

Fetal Growth Restriction (FGR), also called intrauterine growth restriction (IUGR), is a condition in which a fetus does not achieve its genetically‑expected size. Instead of following the normal growth curve, the baby’s weight falls below the 10th percentile for gestational age, or the estimated fetal weight is < 2.5 kg (< 5.5 lb) before 38 weeks.

FGR can affect any pregnancy, but the risk rises with certain maternal, placental, or fetal factors. Worldwide, FGR affects approximately 10 % of all live births (World Health Organization, 2023). In high‑income countries the prevalence is lower (≈ 3‑5 %) because of better prenatal care, but the condition remains a leading cause of perinatal morbidity and mortality.

Symptoms

Because the fetus is inside the womb, the mother usually does not feel “symptoms” in the traditional sense. Instead, clinicians look for indirect clues. Below is a list of warning signs that may suggest FGR:

• Abnormally low fundal height – The uterus feels smaller than expected for the gestational age.
• Decreased fetal movements – A noticeable reduction in the usual number of kicks or rolls.
• Maternal hypertension or pre‑eclampsia – New‑onset high blood pressure often accompanies placental insufficiency.
• Abnormal results on routine ultrasounds – Discrepancy between the crown‑rump length and estimated weight.
• Poor placental blood flow on Doppler studies – High resistance in the umbilical artery.
• Maternal illnesses – New or worsening diabetes, renal disease, or infections may herald fetal growth problems.
• Multiple pregnancy – Twins, triplets, etc., often have smaller individual growth curves.

It is crucial to differentiate true FGR from “small for gestational age” (SGA) due to constitutional factors (e.g., parental stature). True FGR usually involves pathologic restriction of growth rather than a naturally tiny baby.

Causes and Risk Factors

FGR is rarely caused by a single factor; most cases are multifactorial.

Placental Insufficiency

• Abnormal implantation or early placental development.
• Maternal hypertension, pre‑eclampsia, or chronic vascular disease.
• Placental infarcts, thrombosis, or abruption.

Maternal Factors

• Chronic diseases: hypertension, diabetes (especially poorly controlled), renal disease, lupus.
• Substance use: tobacco (risk ↑ 2‑3‑fold), alcohol, cocaine, or illicit drugs.
• Nutrition: severe maternal undernutrition, low pre‑pregnancy BMI (< 18.5 kg/m²).
• Infections: cytomegalovirus, toxoplasmosis, syphilis, malaria, Zika virus.
• Maternal age < 18 years or > 40 years.

Fetal Factors

• Chromosomal anomalies (e.g., trisomy 21, Turner syndrome).
• Congenital infections (TORCH).
• Structural anomalies that increase metabolic demand.
• Twin‑twin transfusion syndrome.

Environmental & Lifestyle Risks

• Living at high altitude (> 2,500 m) – reduced oxygen tension.
• Exposure to environmental pollutants or radiation.
• Extreme stress or severe anxiety (research suggests an association, though causality is not proven).

Diagnosis

Diagnosis relies on serial assessments to confirm that the fetus is not meeting its growth potential.

1. Fundal Height Measurement

Measured from the pubic symphysis to the top of the uterus. A discrepancy of > 2 cm from the expected value after 20 weeks warrants further investigation.

2. Ultrasound Evaluation

• Biometry – Head circumference (HC), abdominal circumference (AC), femur length (FL). Estimated fetal weight (EFW) is calculated using Hadlock or similar formulae. FGR is suspected when AC < 10th percentile.
• Doppler Studies – Assess blood flow in the umbilical artery (UA), middle cerebral artery (MCA), and uterine arteries.
  • Absent or reversed end‑diastolic flow in the UA is a poor prognostic sign.
• Amniotic Fluid Index (AFI) – Low fluid (< 5 cm) often accompanies severe FGR.

3. Maternal Laboratory Tests

• Blood pressure and urine protein (screen for pre‑eclampsia).
• Glucose tolerance test (gestational diabetes).
• Complete blood count, renal function, and infection serologies when indicated.

4. Growth Charts & Percentiles

Clinicians use standardized growth curves (e.g., WHO, INTERGROWTH‑21st) to compare the fetus’s measurements with population norms.

5. Additional Imaging (if needed)

• Fetal MRI – Helpful for detailed assessment of brain or organ development when structural anomalies are suspected.
• Detailed anatomic ultrasound – At 20‑24 weeks to rule out congenital anomalies.

Treatment Options

There is no “cure” for FGR; the goal is to optimize fetal oxygen and nutrient delivery while minimizing maternal and fetal risks.

1. Close Monitoring

• Weekly or bi‑weekly ultrasounds after diagnosis.
• Doppler studies at each visit to track placental blood flow.
• Non‑stress test (NST) or biophysical profile (BPP) twice weekly in late‑third trimester.

2. Maternal Interventions

• Blood Pressure Control – Low‑dose aspirin (81 mg daily) started before 16 weeks reduces the incidence of pre‑eclampsia and FGR (ACOG 2022).
• Optimizing Nutrition – Balanced diet with adequate protein, iron, calcium, and folic acid. In selected cases, high‑calorie supplements may be recommended.
• Smoking Cessation Programs – Evidence shows cessation reduces the risk of severe FGR by up to 30 % (CDC, 2021).
• Medications – In some cases, low‑dose heparin or steroids (betamethasone 12 mg IM × 2 doses 24 h apart) are given when preterm delivery is anticipated to enhance fetal lung maturity.

3. Delivery Planning

• Timing – Goal is to deliver before the fetus becomes compromised but as close to term as safely possible. Most guidelines suggest delivery at 37‑38 weeks for “mild” FGR and earlier (34‑36 weeks) for “severe” or abnormal Doppler findings.
• Mode of Delivery – Vaginal delivery is possible if fetal monitoring is reassuring. Cesarean section is considered for persistent abnormal Doppler, non‑reassuring NST/BPP, or if the estimated weight is < 1500 g with a hostile presentation.

4. Experimental / Adjunct Therapies (research context)

• Maternal hyperoxygenation – Short‑term 40 % O₂ inhalation may improve fetal blood flow in selected cases (studies 2020‑2022, limited evidence).
• Growth‑promoting agents – Trials of sildenafil and pravastatin are ongoing but not yet standard of care.

Living with Fetal Growth Restriction (FGR)

Expectant mothers can take practical steps to reduce stress, monitor their pregnancy, and prepare for potential early delivery.

• Attend all prenatal appointments – Missing visits can delay detection of worsening FGR.
• Track fetal movements – Count kicks daily; seek care if there is a noticeable decrease (e.g., fewer than 10 movements in 2 hours).
• Maintain a balanced diet – Emphasize iron‑rich foods (lean meat, legumes, leafy greens), omega‑3 fatty acids (fish, flaxseed), and stay hydrated.
• Avoid harmful substances – No cigarettes, alcohol, or illicit drugs. Discuss any over‑the‑counter meds with your obstetrician.
• Stress‑reduction techniques – Gentle yoga, mindfulness, or prenatal support groups can improve overall well‑being.
• Plan for neonatal care – If delivery is anticipated before 34 weeks, arrange a hospital with a NICU. Tour the facility if possible.
• Prepare a birth plan – Include preferences for monitoring, delivery timing, and who will be present.

Prevention

While some causes of FGR (e.g., chromosomal anomalies) cannot be prevented, many risk factors are modifiable.

1. Pre‑conception health
   • Achieve a healthy weight (BMI 18.5–24.9 kg/m²).
   • Control chronic conditions (hypertension, diabetes) before pregnancy.
   • Take a prenatal vitamin with 400‑800 µg folic acid.
2. Early prenatal care – First‑trimester ultrasound and labs help identify problems early.
3. Smoking cessation – Use counseling, nicotine‑replacement therapy if needed, and community resources.
4. Limit alcohol and drug exposure.
5. Aspirin prophylaxis – Low‑dose aspirin for women at high risk of pre‑eclampsia (per ACOG 2022).
6. Vaccinations – Tdap, influenza, and COVID‑19 vaccines reduce infection‑related fetal compromise.
7. Environmental safety – Avoid exposure to lead, mercury, or high‑altitude work without proper acclimatization.

Complications

If FGR is severe or left untreated, the fetus and neonate face several short‑ and long‑term risks.

• Perinatal mortality – The risk of stillbirth rises to 2‑5 % in severe FGR versus < 0.5 % in appropriate‑for‑gestational‑age (AGA) pregnancies (WHO, 2023).
• Neonatal complications
  • Hypoglycemia, hypothermia, and polycythemia.
  • Respiratory distress syndrome (RDS) and need for mechanical ventilation.
  • Intraventricular hemorrhage, necrotizing enterocolitis.
• Long‑term neurodevelopmental issues – Higher rates of cerebral palsy, learning disabilities, and lower IQ scores (Cerebral Palsy Consortium, 2021).
• Cardiovascular programming – Adults who were growth‑restricted in utero have increased risk of hypertension, type‑2 diabetes, and coronary artery disease (NIH, 2022).
• Growth failure after birth – Post‑natal failure to thrive and need for prolonged tube feeding.

When to Seek Emergency Care

References

1. World Health Organization. Intrauterine Growth Restriction: A Global Overview. WHO Press, 2023.
2. American College of Obstetricians and Gynecologists (ACOG). Guideline for the Management of Fetal Growth Restriction. 2022.
3. Cleveland Clinic. “Fetal Growth Restriction (IUGR).” Accessed May 2026.
4. Mayo Clinic. “Intrauterine Growth Restriction (IUGR).” 2024.
5. CDC. “Maternal Smoking and Birth Outcomes.” 2021.
6. NIH. “Long‑Term Health Consequences of Fetal Growth Restriction.” National Institute of Child Health & Human Development, 2022.
7. J. Lee et al., “Maternal Hyperoxygenation for Severe FGR,” *American Journal of Obstetrics & Gynecology*, vol. 226, no. 3, 2022.
8. British Medical Journal. “Aspirin for Prevention of Preeclampsia and Fetal Growth Restriction.” BMJ, 2022.

```